Compare
Side by side
Pick up to three peptides to see how their mechanisms, studied uses and evidence levels differ. Rows where the entries disagree are marked with a blue edge.
Selected 1 of 3
Comparison
Thymalin
Immune
Evidence level
Anecdotal evidence
Approval status
Not approved
Mechanism of action
- 1.A peptide extract of calf thymus, containing a mixture of short thymic peptides rather than one defined molecule.
- 2.Proposed to support T-cell maturation and immune regulation, since the thymus is where T cells develop.
- 3.Russian research reports normalised immune markers in elderly patients.
- 4.Because the product is a mixture, its active components and doses are not standardised between batches.
- 5.No mechanism has been confirmed in controlled Western studies.
Studied for
- Immune ageing and recurrent infection claims
- Post-illness recovery in Russian practice
- Thymic peptide research
- No controlled Western trials exist
Reported effects
- Reported improvements in immune markers in Russian studies
- Reported fewer infections in user accounts
- No verified clinical effect in independent trials
Side effects
- Not systematically studied
- Injection-site reactions
- Allergic reactions to animal-derived material are possible
- Long-term safety and batch consistency unknown
Research protocol
Research context only — there is no approved protocol. Russian publications describe intramuscular courses of 5–10 mg daily for 5–10 days, repeated every few months; these are not validated regimens and product composition varies by manufacturer. No human safety data from regulated trials exist.
Research context only
Evidence justification
The evidence base is Russian-language animal and small clinical work that has not been independently replicated; there are no peer-reviewed controlled trials in English.